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Abstract
Background: The National Comprehensive Cancer Network clinical practice guidelines in oncology-gastric cancer
guidelines have been widely used to provide appropriate recommendations for the treatment of patients with
gastric cancer. The aim of this study was to examine the adherence of surgical oncologists, medical oncologists,
and radiation oncologists’ to the recommended guidelines.
Methods: A questionnaire asking the treatment options for gastric cancer cases was sent to 394 Chinese oncology
specialists, including surgical oncologists, medical oncologists, and radiation oncologists working in hospitals joined
in The Western Cooperative Gastrointestinal Oncology Group of China. The questionnaire involved a series of
clinical scenarios regarding the interpretation of surgery, neoadjuvant, adjuvant, and advanced treatment planning
of gastric cancer.
Results: Analysis of 358 respondents (91%) showed variations between each specialization and from the
recommended guidelines in the management approaches to specific clinical scenarios. The majority of specialists
admitted that less than 50% of patients received multidisciplinary evaluation before treatment. The participants
gave different responses to questions involving adjuvant, neoadjuvant, and advanced settings, compared to the
recommended guidelines.
Conclusions: These results highlight the heterogeneity of the treatment of gastric cancer. Surgical oncologists,
medical oncologists, and radiation oncologists are not adhering to the recommended guidelines.
Background
Despite the downward trend for cancer incidence and
mortality in most countries, gastric cancer has become the
second leading cause of cancer-related deaths worldwide
with an annual rate of 700,000 deaths [1]. Almost two-
thirds of the cases occur in developing countries, with 42%
occurring in China alone, where gastric cancer remains
the most deadly cancer among both sexes [2].
Surgical resection, chemotherapy and radiotherapy are
mainstay of treatment for patients with gastric cancer
[3-5]. However, several questions concerning the treat-
ment of gastric cancer remain. First, the type of resection
and the role of extensive lymphadenectomy have been the
subjects of international debate. Second, is there an ideal
setting or regimen that predicts whether chemotherapy
and/or radiotherapy should be provided before and/or
after surgery as (neo) adjuvant treatment in patients with
localized disease? Finally, there is no internationally
accepted standard of care for patients with metastatic and
advanced cancer, and uncertainty remains regarding the
choice of the regimens [6,7].
Clinical practice guidelines in oncology were devel-
oped to ensure quality cancer care throughout the
world. Several global organizations have developed clini-
cal practice guidelines for the treatment and manage-
ment of gastric cancer. These groups include the
National Comprehensive Cancer Network (NCCN) [8],
the European Society of Clinical Organization [9], and
the Japanese Gastric Cancer Association [10]. The
NCCN gastric cancer guidelines (the Guidelines) have
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treatment between different institutions for the treat-
ment of patients with gastric cancer. However, we found
in multidisciplinary team specialists from different
department usually give different recommendations for
surgery, neoadjuvant, adjuvant, and advanced treatment
planning for patients. Until now no studies have been
carried out in regard to variations of the clinical man-
agement of gastric cancer. Accordingly, the aim of this
study was to examine the adherence of surgical oncolo-
gists, medical oncologists, and radiation oncologists’ to
the Guidelines.
Methods
Survey development
The inclusion criterions were as follows: (1) All partici-
pants were oncology specialists, which included surgical
oncologists, medical oncologists, and radiation oncolo-
gists who mainly treat gastric cancer patients. (2) Sub-
jects must have worked in an oncology specialist field
for at least five years; and (3) Subjects should be well
enough to provide informed consent and finish the
questionnaire. Criteria for exclusion were (1) subjects
with gastric cancer themselves or (2) participants who
did not complete their questionnaire for any reason.
Before administration, the questionnaire was pilot tested
using 20 oncology clinicians, and then revised for clarity
and ease of comprehension. The questionnaire con-
tained a total of 32 questions. The first five questions
were related to the oncologists and their hospital char-
acteristics, including demographic information (gender,
age), and their training and educational backgrounds.
The participants were asked “What percentage of your
patients undergoes a multidisciplinary evaluation before
treatment?” Then, individual items were constructed to
measure participants’ adherence to the Guidelines in
medical practice. Questions 7 to 11 were related to sur-
gical options, including the type of resection (total gas-
trectomy or subtotal gastrectomy), the adequate margin
in complete resection, and the extent of lymph node
dissection. There were three additional questions asking
about the follow-up of patients after complete resection.
T h eq u e s t i o n n a i r et h e np r e s e n t e dan u m b e ro fc l i n i c a l
scenarios and elicited the appropriate treatment recom-
mendations using various forms of adjuvant therapy,
neoadjuvant therapy, and advanced options, respectively.
Data collection
The study was approved by the institutional review
board of the West China Hospital, Sichuan University,
China. Questionnaires were handed out to all eligible
participants working in hospitals joined in The Western
Cooperative Gastrointestinal Oncology Group of China,
a cooperative group consortium of affiliated hospitals of
universities and large medical centers in the west of
China.
Questionnaires were handed out to all eligible partici-
pants at the same time at each site. All of them were
given information explaining the study and asked not to
share their answers with their colleagues. Participants
themselves without signing should complete question-
naires to ensure that investigators did not know their
name when the data were analyzed. Participants were
asked to finish and hand in the survey on the spot. All
answers were entered into a computerized database by
two independent people. Then the data were analyzed
by an independent investigator, a third person who had
nothing to do with the data collection. The survey is
attached as additional file 1 to this paper.
Statistical analysis
Comparisons between answers from surgical oncologists,
medical oncologists, and radiation oncologists respon-
dents are mainly based on Chi-square, and Wilcoxon
r a n ks u mt e s ta sa p p r o p r i a t e .C h i - s q u a r et e s ti sp e r -
formed for the categorical data, and Wilcoxon rank sum
test is used for the ordinal data [11]. The significance
level was set at P < 0.05. SPSS statistic software (Version
13.0) was used for data analysis.
Results
Characteristics of oncology specialists and centers
Three hundred ninety-four oncology clinicians were
initially invited to participate in this study. Three hun-
dred sixty-three responses were received, of which 358
were useable (response rate: 91%). Five (1.27%) partici-
pants responded but did not complete their question-
naires. Thirty-one (7.87%) oncology specialists did not
hand in their questionnaire. The median age of the par-
ticipants was 40 years (range 29-68 years). The study
consisted of 161 (44.97%) medical oncologists, 101 sur-
gical oncologists, and 96 radiation oncologists. About
half of the participants had worked in an oncology spe-
cialty for more than 15 years. There were more partici-
pants from university hospitals. The characteristics of
the participants and centers are summarized in Table 1.
Practice variation in clinic
Multidisciplinary evaluation
The participants were asked to estimate what percen-
tages of their patients undergo multidisciplinary evalua-
tion before treatment. The majority reported that less
than half of all patients received multidisciplinary eva-
luation before treatment. Only 10 (2.79%) and 26
(7.26%) of participants reported that 50-75% or > 75%
of their patients undergo multidisciplinary evaluation
before treatment, respectively. Furthermore, we found
there was no difference in this question between
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general hospitals (P = 0.325). However, participants with
a short time in practice (< 15 y) were more likely to
give their patients multidisciplinary evaluation (P =
0.009).
Principles of surgical treatment
When it came to selecting the type of surgery, almost all
the surgical oncologists selected subtotal gastrectomy for
the clinical scenario involving a patient with distal gas-
tric cancer. Most surgical oncologists (76.24%, n = 77)
thought that 5 cm was an adequate margin for complete
resection of gastric cancer, while D2 dissection was con-
sidered an essential procedure by 89 (88.12%) surgical
oncologists. Seventy-three (72.28%) thought at least 15
lymph nodes should be removed. These responses were
consistent with the Guidelines [8]. However, the surgical
procedure of choice for proximal gastric cancer was
more controversial, as mentioned in the Guidelines [8].
Interestingly, the responses of the medical oncologists
and radiation oncologists vary greatly with regards to
the type of gastrectomy and the extent of the lymph
node dissection. Table 2 summarizes the choices for the
clinical scenarios related to surgery posed to the oncol-
ogy specialists.
Principles of neoadjuvant treatment
Table 3 represents the data regarding options for neoad-
juvant treatment. The Guidelines recommend neoadju-
vant chemotherapy for patients with stage T2-4, or N+
[8]. Just under half (47.52%) of the oncological surgeons
selected neoadjuvant chemotherapy and 12.87% selected
preoperative chemoradiation for the clinical scenario of
a patient with stage cT4N0M0. Similarly, some surgical
oncologists selected neoadjuvant chemotherapy (17.82%)
or chemoradiation (12.87%) for a patient with local
lymph node metastasis. None of the participants
selected radiotherapy alone as neoadjuvant treatment.
Preference for a chemotherapy regimen varied greatly.
There was very little difference in the responses regard-
ing the duration of neoadjuvant treatment among medi-
cal oncologists, radiation oncologists, and surgical
oncologists (P = 0.21), and this is consistent with the
Guidelines [8].
Principles of adjuvant treatment
The Guidelines recommend adjuvant chemoradiation for
patients with stages T3-4, or N+, after R0 resection [8]. All
the medical oncologists and radiation oncologists recom-
mended adjuvant treatment for the clinical scenario invol-
ving a patient with stage pT4N0M0, while 18% of surgical
oncologists chose to observe the patient instead of adju-
vant treatment. Moreover, there were differences between
medical oncologists and radiation oncologists in terms of
adjuvant treatment options. For those patients staged as
T2N0M0 with high risk features, such as poorly differen-
tiated or higher grade cancer, lymphovascular invasion, or
< 50 years of age, the Guidelines recommend observation,
adjuvant chemotherapy, or adjuvant chemo-radiation [8].
Surgical oncologists appeared to pay more attention to the
extent of the lymph node dissection, with approximately
70% stating that they would give adjuvant treatment to a
patient who has only six lymph nodes excised. In contrast,
medical oncologists and radiation oncologists were more
likely to give adjuvant treatment to patients with poorly
differentiated and lymphovascular invasion. However, they
were also more likely to observe a patient who has an
inadequate lymph node dissection without adjuvant treat-
ment. The participants were highly consistent on the start
time and duration of adjuvant chemotherapy, which the
Guidelines do address [8]. However, the preference of
which chemotherapy regimen varies greatly. Table 4 sum-
marizes the data regarding the options for adjuvant treat-
ment after complete resection.
Principles of follow-up
Table 5 represents the responses to questions about fol-
low-up. There appeared to be a uniform consensus among
participants on the question concerning follow-up, but the
answers were different from the Guidelines [8], to some
extent. More than half of the participants recommended a
patient undergo follow-up every 2-3 months for the first 3
years, then once every year, while the Guidelines recom-
mend every 4-6 months for the first 3 years, then annually
[8]. All the participants in this investigation stated that
they would undertake a complete medical history, physical
examination, and complete blood count. The majority
reported that they would test the patient’s hepatic and
renal function, and endoscopy. All the oncological sur-
geons selected abdominal CT scan, while less than half
would ask for a chest CT scan. In contrast, medical oncol-
ogists and radiation oncologists tended to select chest
CT scan as well as an abdominal CT scan. However, only
Table 1 Oncology Specialists and Center Characteristics
Respondents
Characteristics N %
Number of respondents 358 90.86
Sex
Male 206 57.54
Female 152 42.46
Specialty
Medical oncologists 161 44.97
Oncological surgeons 101 28.21
Radiation oncologists 96 26.82
Number of years as an oncology clinician
15 years or less 177 49.44
More than 15 years 181 50.56
Practice setting
General hospital 126 35.20
University hospital 232 64.80
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B12 and trace elements along with electrolytes. The
majority of participants would recommend that patients
take supplements such as iron, vitamin B12, and trace
elements.
Principles of palliative treatment
More than 70% of the participants in our study recom-
mended a liver resection and systemic chemotherapy for
a patient presented with a solitary liver metastases. It is
interesting that almost all the participants agreed to give
intraperitoneal chemotherapy and systemic chemother-
apy for an advanced gastric cancer patient with large
ascites, although the Guidelines do not address intraperi-
toneal chemotherapy. The Guidelines recommend tax-
anes based regimens or ECF regimen with category 1
recommendation [8]. When asked, “What was their
choice as the first line chemotherapy regimen?”,t h ef i r s t
three choices for first line chemotherapy by surgical
oncologists and medical oncologists were the same: oxali-
platin based regimen, paclitaxel or docetaxel based regi-
men, and ECF. On the other hand, radiation oncologists
selected the paclitaxel or docetaxel based regimen,
oxaliplatin based regimen, and irinotecan based regimen.
There is no established second, or third-line therapy
according to the Guidelines [8]. The majority of the par-
ticipants in this study would recommend the second or
third line chemotherapy when the patient’s performance
status (PS) is good. The percentage of participants who
tend to give best supportive care instead of chemotherapy
increases for a patient with worse PS. Table 6 sum-
marizes the responses to questions about treatment of
patients with advanced gastric cancer.
Discussion
Quality cancer care depends on research findings, treat-
ment improvements, and practice guidelines. Clinical
guidelines have been designed to maximize the effective-
ness of care as an important tool in evidence based prac-
tice, may reduce inappropriate variations in treatment
approaches, and allow for continuous monitoring of
appropriate care delivery. However, the practice guidelines
are wasted unless they are used in everyday practice by
clinical oncologists [12-14]. In this study, we found consid-
erable variation when comparing the recommendations of
Table 2 Comparison of surgery practice
Surgery practice Recommendation of the Guidelines Oncological
surgeons
Medical
oncologists
Radiation
oncologists
p
N % N%N%
proximal cancer cT2N0M0 Subtotal gastrectomy 0.329
Total gastrectomy 34 33.66 69 42.86 37 38.54
Subtotal gastrectomy 67 66.33 92 57.14 59 61.46
antrum cancer cT2N0M0 Controversial: total or subtotal
gastrectomy
<
0.001
Total gastrectomy 4 3.96 36 22.36 33 34.38
Subtotal gastrectomy 97 96.04 125 79.64 63 65.63
Adequate margin 5 cm <
0.001
2 cm 0 0 4 2.48 3 3.13
3 cm 8 7.92 19 11.80 8 8.33
4 cm 14 13.86 41 25.47 23 23.96
5 cm 77 76.24 58 36.02 33 34.38
6 cm 2 1.98 17 10.56 14 14.58
unclear 0 0 22 13.66 15 15.63
Extent of lymph nodes dissection D2 0.748
D1 0 0 14 8.70 8 8.33
D2 89 88.12 94 58.39 61 63.54
Greater than D2 12 11.88 37 22.98 15 15.63
unclear 0 0 16 9.94 12 12.50
at least how many regional lymph nodes should be
removed
15 0.041
12 0 0 11 6.83 0 0
15 73 72.28 68 42.24 44 45.83
20 19 18.81 46 28.57 39 40.63
30 9 8.91 13 8.07 0 0
unclear 0 0 23 14.29 13 13.54
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Neoadjuvant practice Recommendation of the Guidelines Oncological
surgeons
Medical
oncologists
Radiation
oncologists
p
N%N % N%
adenocarcinoma cT4N0M0 gastrectomy or preoperative chemotherapy 0.612
gastrectomy 40 39.60 75 46.58 27 28.13
preoperative chemotherapy 48 47.52 72 44.72 41 42.71
preoperative radiotherapy 0 0 0 0 0 0
preoperative chemoradiation 13 12.87 14 8.70 28 29.17
adenocarcinoma cT2N2M0 gastrectomy or preoperative chemotherapy 0.040
gastrectomy 70 69.31 77 47.83 30 31.25
preoperative chemotherapy 18 17.82 73 45.34 38 39.58
preoperative radiotherapy 0 0 0 0 0 0
preoperative chemoradiation 13 12.87 11 6.83 28 29.17
regimen usually used in neoadjuvant setting ECF(EPI+DDP+5FU) 0.634
CF(DDP+5FU) 21 20.79 29 18.01 15 15.63
ECF(EPI+DDP+5FU) 15 14.85 35 21.74 14 14.58
fluoropyrimidine(5Fu or Capecitabine) 24 23.76 7 4.35 7 7.30
oxaliplatin based regimen 23 22.77 63 39.13 35 36.46
irinotecan based regimen 12 11.88 5 3.11 9 9.38
paclitaxel or docetaxel based regimen 6 5.94 22 13.66 16 16.67
combination of above or other 0 0 0 0 0 0
how long neoadjuvant chemotherapy last 3 cycles, about 2 months 0.213
< 1 m 21 20.79 19 11.80 8 8.33
1-3 m 76 75.25 127 78.88 79 82.29
> 3 m 4 3.96 15 9.32 9 9.38
Table 4 Medical decision making on adjuvant treatment
Adjuvant practice Recommendation of the
Guidelines
Oncological
surgeons
Medical
oncologists
Radiation
oncologists
p
N%N % N %
moderately differentiated adenocarcinoma pT4N0M0 after
gastrectomy
postoperative
chemoradiation
0.007
observe without postoperative treatment 19 18.81 0 0 0 0
postoperative chemotherapy 57 56.44 102 63.35 26 27.08
postoperative radiotherapy 0 0 0 0 7 7.29
postoperative chemoradiation 25 24.75 59 36.65 63 65.63
moderately differentiated adenocarcinoma pT4N0M0 after
gastrectomy
Systemic chemotherpy <
0.001
Systemic chemotherapy 73 72.28 89 55.28 75 78.13
Intraperitoneal chemotherapy(IP) 0 0 0 0 0 0
Systemic chemotherapy+IP 28 27.72 72 44.72 21 21.88
Other 0 0 0 0 0 0
moderately differentiated adenocarcinoma invaded muscularis and
vascular without metastasis in the 16 removed regional lymph nodes
postoperative
chemotherapy
0.044
observe without postoperative treatment 41 40.59 37 22.98 26 27.08
postoperative chemotherapy 46 45.54 73 45.34 38 39.58
postoperative radiotherapy 0 0 0 0 13 13.54
postoperative chemoradiation 14 13.86 51 31.68 19 19.79
other 0 0 0 0 0 0
poor differentiated adenocarcinoma invaded muscularis without
metastasis in the 16 removed regional lymph nodes
postoperative
chemotherapy
0.053
observe without postoperative treatment 52 51.49 21 13.04 17 17.71
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specialists.
In recent years, a series of studies in various cancers
demonstrated that multidisciplinary care could achieve
greater resource efficiency and improve standards of care
through a reduction in duplication and gaps in service pro-
vision, enabling the delivery of holistic services and better
continuity of care [15]. Effective multidisciplinary team
functioning is important not only for the benefit of patients,
but also for the efficiency, morale, and work satisfaction of
the individual team members [16]. Multidisciplinary care
has become the standard in cancer management, which is
supported by national and international clinical practice
guidelines in many countries [17]. The management of gas-
tric cancer usually requires the expertise of several disci-
plines, including surgical oncology, radiation oncology,
medical oncology, nutritional support, and endoscopic
expertise. The Guidelines encourage a multidisciplinary
evaluation for the treatment of patients with gastric cancer
[8]. However, approximately 90% of the participants of our
survey reported that less than half of all patients received
multidisciplinary evaluation before treatment. Through
stratification analysis, we found that there was no difference
between participants from university hospitals and those
from general hospitals, but participants with a short time in
practice (5-15 y) were more likely to have their patients to
receive multidisciplinary evaluation. Perhaps experienced
clinicians are more confident in making treatment deci-
sions alone.
The type of resection and the role of extensive lympha-
denectomy have been the subject of debate according to
the Guidelines [8]. In this study, D2 dissection was gener-
ally considered as an essential procedure, however, surgi-
cal oncologists have different ideas as to the surgical
Table 4 Medical decision making on adjuvant treatment (Continued)
postoperative chemotherapy 43 42.57 140 86.96 58 60.42
postoperative radiotherapy 3 2.97 0 0 0 0
postoperative chemoradiation 3 2.97 0 0 21 21.88
other 0 0 0 0 0 0
well differentiated adenocarcinoma invaded muscularis without
metastasis in the 6 removed regional lymph nodes
observe without
postoperative treatment
0.020
observe without postoperative treatment 29 28.71 68 42.24 36 37.50
postoperative chemotherapy 66 65.35 61 37.89 36 37.50
postoperative radiotherapy 0 0 0 0 5 5.21
postoperative chemoradiation 6 5.94 32 19.88 19 19.79
other 0 0 0 0 0 0
when begin adjuvant chemotherapy after gastrectomy NA 0.233
1-2 w 13 12.87 28 17.39 11 11.46
3-4 w 82 81.19 133 82.61 79 82.29
5-6 w 4 3.96 0 0 6 6.25
≥ 6 w 2 1.98 0 0 0 0
regimen usually used in adjuvant setting (without neoadjuvant
chemotherapy)
CF(DDP+5FU) or
fluoropyrimidine(5Fu or
Capecitabine)
0.383
CF(DDP+5FU) 18 17.82 21 13.04 12 12.50
ECF(EPI+DDP+5FU) 12 11.88 25 15.53 7 7.29
fluoropyrimidine(5Fu or Capecitabine) 12 11.88 11 6.83 11 11.46
oxaliplatin based regimen 34 33.66 69 42.86 44 45.83
irinotecan based regimen 20 19.80 8 4.97 9 9.38
paclitaxel or docetaxel based regimen 5 4.95 24 14.91 8 8.33
combination of above or other 0 0 3 1.86 5 5.21
how long adjuvant chemtherapy last NA 0.220
1-3 m 11 10.89 2 1.24 11 11.46
4-6 m 71 70.30 144 89.44 63 65.63
7-9 m 7 6.93 3 1.86 7 7.29
10-12 m 5 4.95 5 3.11 8 8.33
≥ 12 m 3 2.97 4 2.48 7 7.29
3-6 m in the first year, then 2-3 m annually for 2-3 y 4 3.96 3 1.86 0 0
other 0 0 0 0 0 0
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trectomy options for proximal gastric cancer, the extent of
the lymph nodes dissection, and what is an adequate surgi-
cal margin. There are more controversial issues with
regards to the treatment principles among medical oncol-
ogists and radiation oncologists, with many of them unfa-
miliar with the principals of surgery. In addition, the
participants provided different selections for questions on
the adjuvant, neoadjuvant, and advanced settings, com-
pared to the Guidelines.
A number of factors are considered during the process
of formulating a treatment plan for gastric cancer
patients: Most importantly, how well a clinician adheres
to the practice guidelines depends largely on the strength
of the evidence supporting clinical practice. If a clinician
finds that the evidence is scant or if the evidence is not
suitable for their patients, then they could not adhere to
the guidelines. We have found evidence to support this
issue in this study. For example, the role of adjuvant ther-
apy for gastric cancer has been controversial given the
lack of high level, worldwide evidence. Although numer-
ous phase III studies, including a surgery-only group,
have been reported in the last three decades, definitive
evidence of the efficacy of postoperative chemotherapy is
lacking [18]. The first positive, large scale phase III trial
by the Adjuvant Chemotherapy Trial of S-1 for Gastric
Cancer (ACTS-GC) group reported the superiority of S-1
as an adjuvant chemotherapy over surgery alone after D2
lymph node dissection in a Japanese population [19]. The
effect of adjuvant chemotherapy outside of East Asia is
uncertain, and standard management following curative
surgery is heterogeneous throughout the world [18].
Recent meta-analyses have suggested a small benefit of
adjuvant therapy, but the widely varying regimens and
populations from the studies included in these meta-ana-
lyses have limited their impact [6,7,18,20,21]. In addition,
Table 5 Medical decision making on follow-up
Follow-up practice Recommendation of the Guidelines Oncological
surgeons
Medical
oncologists
Radiation
oncologists
p
N%N % N %
how often follow-up Every 4-6 m for 3 y, then annually 0.086
Every 4-6 m for 3 y, then
annually
9 8.91 18 11.18 7 7.29
Every 4-6 m for 5 y, then
annually
13 12.87 25 15.53 11 11.46
Every 2-3 m for 3 y, then
annually
64 63.37 94 58.39 63 65.63
Every 2-3 m for 5 y, then
annually
12 11.88 19 11.80 14 14.58
other 3 2.97 5 3.11 1 3.13
which included in the follow-
up (multiple answers)
Complete history and physical examination for all the patients,
CBC, platetets, radiologic imaging or endoscopy as clinically
indicated, monitor Vit B12 for proximal or total gastrectomy
patitnts
0.371
Complete history and physical
examination
101 100 161 100 96 100
CBC, Hb, platetets 101 100 161 100 96 100
Hepatic and renal function 101 100 154 95.65 91 94.79
Endoscopy 92 91.09 123 76.40 86 89.58
Chest CT 46 45.54 156 96.89 88 91.67
Abdominal CT 101 100 160 99.38 93 96.88
Vit B12 29 28.71 34 21.12 26 27.08
Trace elements and
electrolytes
18 17.82 29 18.01 19 19.79
Other 0 00000
which recommended as food
supplementation (multiple
answers)?
Vit B12 for proximal or total gastrectomy patitnts 0.786
Iron 101 100 159 98.76 82 85.42
Trace elements and
electrolytes
71 70.30 128 79.50 74 77.08
Vit B12 101 100 161 100 95 98.96
Other 0 00000
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lines was the intergroup trial INT-0116 [22]. However,
90% of the patients enrolled in this study received D0
(54%) or D1 (36%) dissection, while D2 dissection is
widely performed in China. It is estimated that the radia-
tion in INT-0116 makes up for the inadequacy of surgery.
Again, intraperitoneal chemotherapy was widely accepted
by the participants in this study while it was not
addressed in the Guidelines at all. This may be explained
by the geographical variation in standard practice, which
really exists. For instance, adjuvant oral fluoropyrimidine
monotherapy following radical D2 resection is the stan-
dard care of stage II-III gastric cancer in Japan. In Eur-
ope, combination chemotherapy delivered before and
after D2 resection is the most widely accepted practice,
and in the USA, patients will routinely be referred for
adjuvant chemoradiation following resection [23]. There
is no worldwide, high-level evidence on the treatment of
gastric cancer, hence, it can be expected that clinicians
do not adhere to the Guidelines. Secondly, some of this
variation appears to represent professional preferences.
Recent studies have shown that perioperative chemother-
a p yy i e l d sas u b s t a n t i a lp a t h o l o g i cr e s p o n s et h a tr e s u l ti n
durable survival time [24]. The British Medical Research
Council performed the first well-powered phase III trial
(MAGIC trial) for perioperative chemotherapy [25]. The
result has established perioperative chemotherapy as an
option for the standard of care of patients with resectable
gastric cancer, according to the Guidelines [8]. In our
study, there were few surgical oncologists who preferred
Table 6 Medical decision making on advanced treatment
Advanced practice Recommendation of the Guidelines Oncological
surgeons
Medical
oncologists
Radiation
oncologists
p
N%N % N %
adenocarcinoma with solitary liver metastases Systemic chemotherpy 0.443
Systemic chemotherpy 4 3.96 7 4.35 5 5.21
Liver lesion resection 8 7.92 16 9.94 5 5.21
TACE 10 9.90 21 13.04 15 15.63
Liver lesion resection + systemic chemotherpy 79 78.22 117 72.67 68 70.83
Other 0 0 0 0 3 3.13
adenocarcinoma with large quantity of ascites Systemic chemotherpy 0.210
Systemic chemotherapy 3 2.97 2 1.24 2 2.08
intraperitoneal chemotherapy(IP) 4 3.96 6 3.73 5 5.21
Systemic chemotherapy+IP 94 93.07 153 95.03 89 92.71 0.254
Other 0 0 0 0 0 0
lungs metastases Paclitaxel or docetaxel based regime or ECF
(EPI+DDP+5FU)
0.070
CF(DDP+5FU) 2 1.98 3 1.86 1 1.04
ECF(EPI+DDP+5FU) 17 16.83 23 14.29 9 9.38
Fluoropyrimidine(5Fu or Capecitabine) 13 12.87 12 7.45 14 14.58
Oxaliplatin based regimen 33 32.67 51 31.68 25 26.04
Irinotecan based regimen 9 8.91 22 13.66 15 15.63
Paclitaxel or docetaxel based regime 25 24.75 46 28.57 29 30.21
Combination of above or other 2 1.98 4 2.48 3 3.13
lungs metastases, failure after ECF(EPI+DDP+5FU) Change regimen and continue chemotherapy
Change regimen and continue chemotherapy 101 100 156 96.89 83 86.46 0.137
Best supportive care 0 0 2 1.24 9 9.38
Other 0 0 3 1.86 4 4.17
lungs metastases, failure after both ECF and
Paclitaxel+DDP
Change regimen and continue chemotherapy 0.351
Change regimen and continue chemotherapy 86 85.15 122 75.78 60 62.50
Best supportive care 13 12.87 35 21.74 31 32.29
Other 2 1.98 4 2.48 5 5.21
lungs metastases, failure after both ECF and
Paclitaxel+DDP, PS 3
Best supportive care 0.222
Change regimen and continue chemotherapy 18 17.82 15 9.32 9 9.38
Best supportive care 79 78.22 136 84.47 81 84.38
Other 4 3.96 10 6.21 6 6.25
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Page 8 of 10neoadjuvant chemotherapy. Finally, a lack of consistency
among clinicians may also be the result of recognition
error and unfamiliarity with the use of accepted criteria.
In this study, a few medical oncologists and radiation
oncologists were not clear about the surgical principle
behind treating gastric cancer. In addition, the rapid dis-
semination of new knowledge makes it more difficult for
clinicians to keep up to date, and inconsistent reports in
the literature can also contribute to variability in treat-
ment decision making among clinicians.
We acknowledge there are several limitations to the
current analysis. Firstly, we asked participants to answer
b a s e do nw h a tt h e y“usually do with most” of their
patients. However, respondents were more likely to select
“one best answer”. Their answer may be different from
their actual decision-making in the oncology clinic. The
second limitation is that we did not elaborate further on
many of our findings due to our concern about the
length of the survey and ensuring responders’ anonymity.
For example, we did not collect data about institutional
affiliations to explore whether practice was consistent
within the same division. Thirdly, we did not perform
multivariate analyses for each clinical scenario to analyze
differences according to the type of practice (university
vs. other), age, gender, experiences of participants, and
volume of a center, etc. However, these factors could also
affect the clinician’s practice. For example, it was
reported that surgeons who do more gastric resections
per year were more likely to report performing a D2
resection, according to a study in Canada [26]. In addi-
tion, it is unclear whether the area of specialty (surgery
vs. medical) affects the treatment option. We could not
determine from the current study how a surgeon affects
the choices of a chemotherapy regimen or how a medical
oncologist affects the type of resection. Finally, and per-
haps most importantly, several of the scenarios chosen
were purposefully controversial without clear evidence to
suggest one optimal approach.
Nevertheless, we believe that the practice variation
documented here should encourage the planning and
implementation of randomized clinical trials to address
controversial areas of the treatment of gastric cancer. The
significant increase in the quantity of scientific clinical
trials should result in guidelines updated with more cer-
tainty and supporting evidence. This survey should also
encourage specialists in the field of gastric cancer to keep
up to date with new knowledge with a focus on the use of
accepted treatment criteria. More continuing medical edu-
cation programs should be designed to shorten the knowl-
edge gap and improve the quality of care and outcome of
multidisciplinary management. The documentation of
practice variation highlights areas where better education,
dissemination of information, and quality improvement
systems can improve care, as long as the evidence for a
practice has also increased with additional studies.
Conclusions
These results highlight the heterogeneity of the treatment
of gastric cancer. Surgical oncologists, medical oncologists,
and radiation oncologists are not adhering to the recom-
mended guidelines. The study should encourage the plan-
ning and implementation of randomized clinical trials to
address controversial areas of the treatment of gastric can-
cer and to establish updated guidelines with more cer-
tainty and supporting evidence. It should also encourage
the development of more continuing medical education
programs designed to shorten the knowledge gap and to
improve the quality of care and outcome of multidisciplin-
ary management. Specialists in the field of gastric cancer
should keep up to date with new knowledge with a focus
on the use of accepted treatment criteria.
Additional material
Additional file 1: Gastric cancer treatment survey. questionnaires
used in this study.
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